The Making of a cDC1 : Precision Programming of Progenitor Potential
Immunological Reviews · 2026
DOI: 10.1111/imr.70081 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, 2026. Verfasst von Theresa L Murphy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Stem Cells. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 143 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
The development of type 1 classical dendritic cells (cDC1s) from bone marrow progenitors is a multistage process directed by a complex transcriptional network. At its center is interferon regulatory factor‐8 (IRF8), the lineage‐determining factor whose precise, stage‐specific expression is integrated at the Irf8 super‐enhancer. This developmental sequence is initiated in early progenitors by C/EBPα acting at the +56 kb Irf8 enhancer. As progenitors transition to the common dendritic cell progenitor (CDP), the E‐protein activity at the +41 kb Irf8 enhancer further augments the level of IRF8 expression. This progression is followed by a critical “enhancer switch” network, in which NFIL3 induced in the CDP suppresses ZEB2, causing de‐repression of both ID2 and BATF3. This step terminates the +41 kb enhancer's activity while simultaneously engaging the +32 kb enhancer, where newly induced BATF3 forms a stable auto‐regulatory loop with IRF8 and JUN to lock in the cDC1 fate. A notable feature of the +32 kb Irf8 enhancer is its low‐affinity elements that purposely detune factor binding, called suboptimization, a property that is critical for the divergence of the cDC1 and cDC2 progenitors. The development of the cDC1 can also be abrogated in settings that disturb the normal balance of Zeb2 repression by NFIL3 and activation by C/EBP factors. Tumors producing IL‐6 systemically can elevate C/EBPβ in CDPs to a point where NFIL3 fails to induce cDC1 specification. Finally, studies of compound enhancer deletions reveal that this cascade is governed by a strictly cis‐dependent mechanism: the function of each subsequent enhancer is contingent on the successful prior activation of the preceding enhancer on the same chromosome. This sequential, cis‐regulated activation appears to be the core mechanism for progressively tuning chromatin accessibility, ensuring robust lineage commitment. While its molecular basis is obscure, this dependency offers a new model for understanding genomic regulation in development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
ORCID-Profile: Kenneth M Murphy
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Murphy, T. L., & Murphy, K. M. (2026). The Making of a cDC1 : Precision Programming of Progenitor Potential. Immunological Reviews. https://doi.org/10.1111/imr.70081
Vancouver
Murphy TL, Murphy KM. The Making of a cDC1 : Precision Programming of Progenitor Potential. Immunological Reviews. 2026. doi:10.1111/imr.70081
BibTeX
@article{Murphy2026,
author = {Murphy, Theresa L and Murphy, Kenneth M},
title = {The Making of a cDC1 : Precision Programming of Progenitor Potential},
journal = {Immunological Reviews},
year = {2026},
doi = {10.1111/imr.70081}
}
EUVIMED